OaCP is a groundbreaking startup based in Cork, Cork, Ireland that is revolutionizing the way cancer is diagnosed. With patented and CE-IVD chemical reagents, the company is able to reduce the time and cost of DNA tests for cancer diagnosis. In this startup showcase, we take a closer look at how OaCP is using innovative technology to transform cancer diagnosis.
A New Era of Cancer Diagnosis
One of the most exciting aspects of OaCP’s technology is the way it is transforming the field of cancer diagnosis. By reducing the time and cost of genetic testing, the company is helping to ensure that patients receive the care they need as quickly and efficiently as possible.
OaCP’s chemical reagents have been designed specifically for use in DNA tests for cancer diagnosis. The technology is patented and CE-IVD certified, which means that it meets the highest standards of safety and effectiveness. With OaCP’s technology, genetic testing for cancer diagnosis can be completed in just two hours, compared to the three days that it typically takes with other methods.
A Growing Market
OaCP is focused on the Molecular in vitro diagnostics market, starting from the highly competitive USD 1b In situ Hybridization market. With sales of USD 100K and a 100% CRR and 98% GM to hospitals and R&D centres, the company is already making a significant impact in the market.
In addition to its patented technology, OaCP also benefits from a distribution network that covers almost 15 countries globally. This means that the company is able to reach a wide range of customers and provide them with the innovative diagnostic technology they need.
Looking to the Future
OaCP’s team is made up of experts in science, business, marketing, and web communication, who are all committed to driving the company forward. The company has undergone the RebelBio Accelerator program in 2017 and has received USD 330k in funding, mainly from SOS Venture. OaCP has also been awarded in several international competitions, mainly in Hong Kong and China.
Now, OaCP is looking for an investment of Euro 2M to push, expand, and consolidate its market presence. With this investment, the company aims to create a company that is able to grow organically and bring the best diagnostic technology to the greatest number of cancer patients.
Conclusion
Overall, OaCP is a company that is making a significant impact in the field of cancer diagnosis. With its patented and CE-IVD chemical reagents, the company is helping to reduce the time and cost of genetic testing and ensure that patients receive the care they need as quickly and efficiently as possible. As the company continues to grow, it is sure to play a key role in transforming the way cancer is diagnosed and treated.
Website: https://www.oncology-and-cytogenetic-products.com
Twitter: https://www.twitter.com/oacps
Facebook: https://www.facebook.com/oncologyandcytogeneticproducts
LinkedIn: https://www.linkedin.com/company-beta/11107523/
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
